Our laboratory is broadly interested in the connection between tumor innate immunity and oncogenesis. We have discovered key defects essential to the survival of cancer cells and developed novel immune modulating therapies.We have also engineered advanced ex vivo technologies that allow for the evaluation of immune responses in tumor samples, including those obtained directly from patients. The overall goal of our work is to develop novel immunotherapy combinations that can be deployed with increasing precision to improve patient outcomes.